(Q42190478)

18 October 2017

title

Reduction in the size of prolactin-producing pituitary tumor after Cabergoline administration (English)

1 reference

18 October 2017

G B Melis

1

1 reference

18 October 2017

M Gambacciani

2

1 reference

18 October 2017

A M Paoletti

3

1 reference

18 October 2017

V Mais

4

1 reference

18 October 2017

D Sghedoni

5

1 reference

18 October 2017

P Fioretti

6

1 reference

18 October 2017

language of work or name

English

0 references

publication date

1 September 1989

1 reference

18 October 2017

published in

Fertility and Sterility

1 reference

18 October 2017

volume

52

1 reference

18 October 2017

issue

3

1 reference

18 October 2017

page(s)

412-415

1 reference

The effect of lisuride hydrogen maleate in the hyperprolactinaemia-amenorrhoea syndrome: clinical and hormonal responses

18 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960909-3

7 January 2021

Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960909-3

7 January 2021

Treatment of hyperprolactinaemic patients with pergolide

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960909-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960909-3

7 January 2021

The effects of the gabaergic drug, sodium valproate, on prolactin secretion in normal and hyperprolactinemic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960909-3

7 January 2021

Pharmacological activation of gamma-aminobutyric acid-system blunts prolactin response to mechanical breast stimulation in puerperal women

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960909-3

7 January 2021

Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960909-3

7 January 2021

Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960909-3

7 January 2021

Size reduction of extrasellar pituitary tumors during bromocriptine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2816%2960909-3

7 January 2021

10.1016/S0015-0282(16)60909-3

Identifiers

DOI

0 references

1 reference